Skip to Main Content

Orthofix Medical, Inc. (NASDAQ: OFIX) Securities Fraud Class Action

View Complaint
COMPANY       Orthofix Medical, Inc.
COURT United States District Court for the Eastern District of Texas
CASE NUMBER 24-cv-00690
JUDGE The Hon. James Rodney Gilstrap
CLASS PERIOD  October 11, 2022, through September 12, 2023
SECURITY TYPE  Common Stock

LEAD PLAINTIFF DEADLINE IS OCTOBER 21, 2024.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.

Case Background:
On October 11, 2022, Orthofix and SeaSpine Holdings Corporation (“SeaSpine”), announced that they entered into a definitive agreement to combine in an all-stock merger (the “Merger”), with Orthofix being the surviving company.  According to the announcement, SeaSpine’s President and CEO, would serve as President and CEO and be appointed to the Board of Directors of the combined company.  

On November 1, 2022, Orthofix and SeaSpine, announced that, upon the completion of the Merger, SeaSpine’s CFO and COO, and SeaSpine’s Senior Vice President and General Counsel, would serve as CFO and Chief Legal Officer of the combined company, respectively.  On January 4, 2023, Orthofix and SeaSpine announced the successful completion of the Merger.

The complaint alleges that, during the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) Orthofix’s management team was engaged in “repeated inappropriate and offensive conduct that violated multiple code of conduct requirements,” which was also “inconsistent with the Company’s values and culture”; and (2) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On September 12, 2023, Orthofix announced, effective immediately, the appointment of an interim CEO, interim CFO and interim Chief Legal Officer, and the termination of the previously appointed and aforementioned executive officers, following an investigation that determined the “executives engaged in repeated inappropriate and offensive conduct that violated multiple code of conduct requirements and was inconsistent with the Company’s values and culture.”  On this news, the price of Orthofix common stock declined $5.62 per share, or over 30%, from a close of $18.63 per share on September 11, 2023, to close at $13.01 per share on September 12, 2023.

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Complete this form with your transactions in Orthofix Medical, Inc. securities between October 11, 2022, and September 12, 2023.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Orthofix Medical, Inc. prior to the Class Period?
Are you a current or former employee of Orthofix Medical, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email